Eculizumab
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Eculizumab |
| DrugBank ID | DB01257 |
| Brand Names (EU) | Bekemv, Epysqli |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.97% |
Approved Indication (EMA)
Bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | cyclic hematopoiesis | 99.97% | DL |
| 2 | autosomal recessive severe congenital neutropenia due to JAGN1 deficiency | 99.96% | DL |
| 3 | X-linked severe congenital neutropenia | 99.96% | DL |
| 4 | congenital neutropenia-myelofibrosis-nephromegaly syndrome | 99.96% | DL |
| 5 | adult idiopathic neutropenia | 99.96% | DL |
| 6 | autosomal recessive severe congenital neutropenia due to CXCR2 deficiency | 99.96% | DL |
| 7 | primary immunodeficiency syndrome due to p14 deficiency | 99.95% | DL |
| 8 | autosomal recessive severe congenital neutropenia due to CSF3R deficiency | 99.95% | DL |
| 9 | severe congenital neutropenia | 99.95% | DL |
| 10 | primary release disorder of platelets | 99.94% | DL |
| 11 | pseudo-von Willebrand disease | 99.94% | DL |
| 12 | Barth syndrome | 99.91% | DL |
| 13 | Glanzmann thrombasthenia | 99.90% | DL |
| 14 | mixed-type autoimmune hemolytic anemia | 99.89% | DL |
| 15 | drug-induced autoimmune hemolytic anemia | 99.89% | DL |
| 16 | constitutional neutropenia | 99.88% | DL |
| 17 | primary CD59 deficiency | 99.88% | DL |
| 18 | cold agglutinin disease | 99.87% | DL |
| 19 | neonatal autoimmune hemolytic anemia | 99.86% | DL |
| 20 | autosomal recessive severe congenital neutropenia due to G6PC3 deficiency | 99.86% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.